申请人:F. HOFFMANN-LA ROCHE AG
公开号:EP0579066A2
公开(公告)日:1994-01-19
57 Compounds of the formula
wherein
R1 is hydrogen or -(CH2)mCOOR2;
R2 is hydrogen, (R6)2N(CH2)2-, R6COOCH2- or -CH2CON(CH2CH20H)2;
R3 is hydrogen, nitro, hydroxy, amino, CH3(CH2) nS(O)0-2-, CH3(CH2)n-,CH3(CH2)nO- ,R5COO-, RsOOC- ,R5HNCOO-, RsNHCO-, RsCONH-, RsNHCONH-, [CH3(CH2)n]2NCO- , CH3(CH2)nCHOHCH20-, (2-quinolinyl)methoxy, oleyloxy, linoleyloxy, R8OOC(CH2)t-O, (R6 0)2 PO(CH2)pO- , (HO) (R60)PO(CH2)pO- , R6[O(CH2)2]qO- , R7(CH2)pO-, or -O(CH2)p-pyridinium+(OH-);
R4 is CH3(CH2) n- , CH3(CH2)nO- , CF3SO2NH-, RsCOO-, RsOOC- ,R5HNCOO-, RsNHCO-, RsCONH-RsNHCONH-, [CH3(CH2)n]2NCO-, CH3(CH2)nCHOHCH20-, carboxy, (2-quinolinyl)methoxy, oleyloxy, linoleyloxy, R8OOC(CH2)tO-, R6[O(CH2)2]qO- , or R7(CH2)pO-;
R5 is CH3(CH2)n-, 1-adamantyl or diphenylmethyl;
R6 is lower alkyl;
R7 is 1- or 2 -naphthyloxy, 1-, 2- or 3-pyridinyloxy, 2,3- or 3,4-dihydroxyphenyl, 6,7-dihydroxy-2-naphthyl, phenyl, phenoxy or substituted phenyl or phenoxy, wherein the substituent is selected from the group consisting of lower alkyl, lower alkoxy, hydroxy, nitro, amino, halo, R6 S(O)0-2-, carboxy, carboxy-lower alkyl or phenyl;
R8 is hydrogen or lower alkyl;
n is an integer from 0 to 17;
m is an integer from 1 to 3;
t is an integer from 1 to 10;
p is an integer from 2 to 18, and
q is an integer from 1 to 6;
and when R2 is hydrogen, a pharmaceutically acceptable salt thereof with a base, are potent inhibitors of phospholipases A2 (PLA2's) and are therefore useful in the treatment of inflammatory diseases, such as psosiasis, inflammatory bowel disease, asthma, allergy, arthritis, dermatitis, gout, pulmonary disease, myocardial ischemia/reperfusion, and trauma induced inflammation, such as spinal cord injury.
57 式中的化合物
式中
R1 是
氢或-(
CH2)mCOOR2;
R2 是
氢、(R6)2N( )2-、R6COO - 或- CON( 0H)2;
R3 是
氢、硝基、羟基、
氨基、
CH3( )nS(O)0-2-、 ( )n-、 ( )nO-、R5COO-、RsOOC-、R5HNCOO-、RsNHCO-、RsCONH-、RsNHCONH-、[ ( )n]2NCO-、 ( )nCHOH 0-、(2-quinolinyl)methoxy, oleyloxy, linoleyloxy, R8OOC( )t-O, (R6 0)2 PO( )pO-, (HO) (R60)PO( )pO-, R6[O( )2]qO-, R7( )pO-, 或-O( )p-
吡啶鎓+(OH-);
R4 是 ( )n- , ( )nO- ,CF3SO2NH- ,RsCOO- ,RsOOC- ,R5HNCOO- ,RsNHCO- ,RsCONH-RsNHCONH- ,[ ( )n]2NCO- 、R8OOC( )tO-、R6[O( )2]qO- 或 R7( )pO-;
R5 是 ( )n-、1-
金刚烷基或二
苯基
甲基;
R6 是低级烷基
R7 是 1-或 2-
萘氧基,1-、2-或 3-
吡啶氧基,2,3-或 3,4-二羟基
苯基,6,7-二羟基-2-
萘基,
苯基,
苯氧基或取代的
苯基或
苯氧基,其中取代基选自由低级烷基、低级烷
氧基、羟基、硝基、
氨基、卤代、R6 S(O)0-2-、羧基、羧基-低级烷基或
苯基组成的组;
R8 是
氢或低级烷基;
n 是 0 至 17 的整数;
m 是 1 至 3 的整数;
t 是 1 至 10 的整数;
p 是 2 至 18 的整数,和
q 是 1 至 6 的整数;
以及当 R2 为
氢时,其与碱的药学上可接受的盐,是
磷脂酶 A2(P
LA2)的强效
抑制剂,因此可用于治疗炎症性疾病,如
银屑病、炎症性肠病、哮喘、过敏、关节炎、皮炎、痛风、肺部疾病、心肌缺血/再灌注,以及创伤引起的炎症,如脊髓损伤。